Morgan Stanley
NGNE icon

Morgan Stanley’s Neurogene NGNE Stock Holding History

Morgan Stanley’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.75M Sell
285,239
-85,935
-23% -$1.66M ﹤0.01% 4037
2025
Q4 		$7.65M Sell
371,174
-55,402
-13% -$1.38M ﹤0.01% 3852
2025
Q3 		$7.39M Sell
426,576
-119,027
-22% -$2.39M ﹤0.01% 3819
2025
Q2 		$8.16M Buy
545,603
+259,491
+91% +$4.07M ﹤0.01% 3627
2025
Q1 		$3.35M Sell
286,112
-43,751
-13% -$760K ﹤0.01% 4253
2024
Q4 		$7.54M Sell
329,863
-26,562
-7% -$988K ﹤0.01% 3636
2024
Q3 		$15M Sell
356,425
-26,243
-7% -$1.02M ﹤0.01% 3086
2024
Q2 		$13.9M Sell
382,668
-133,940
-26% -$4.72M ﹤0.01% 3043
2024
Q1 		$26.3M Sell
516,608
-163,350
-24% -$5.46M ﹤0.01% 2396
2023
Q4 		$13.2M Buy
679,958
+653,040
+2,426% +$9.35M ﹤0.01% 3694
2023
Q3 		$425K Sell
26,918
-14,181
-35% -$209K ﹤0.01% 5239
2023
Q2 		$682K Buy
41,099
+16
+0% +$262 ﹤0.01% 5052
2023
Q1 		$575K Buy
41,083
+12,962
+46% +$152K ﹤0.01% 5174
2022
Q4 		$286K Sell
28,121
-1,502
-5% -$15.5K ﹤0.01% 5513
2022
Q3 		$379K Sell
29,623
-1,522
-5% -$31.1K ﹤0.01% 5412
2022
Q2 		$641K Sell
31,145
-2,761
-8% -$67.3K ﹤0.01% 5289
2022
Q1 		$1.27M Buy
33,906
+3,906
+13% +$228K ﹤0.01% 4829
2021
Q4 		$2.89M Buy
30,000
+125
+0.4% +$15.2K ﹤0.01% 4274
2021
Q3 		$4.32M Sell
29,875
-1,675
-5% -$256K ﹤0.01% 3896
2021
Q2 		$5.82M Buy
31,550
+14,266
+83% +$3.16M ﹤0.01% 3624
2021
Q1 		$4.26M Sell
17,284
-4,230
-20% -$1.08M ﹤0.01% 3579
2020
Q4 		$6.07M Buy
21,514
+11,903
+124% +$2.91M ﹤0.01% 3050
2020
Q3 		$2.31M Buy
9,611
+5,893
+158% +$1.43M ﹤0.01% 3536
2020
Q2 		$1.24M Buy
3,718
+610
+20% +$159K ﹤0.01% 4002
2020
Q1 		$707K Buy
3,108
+2,984
+2,406% +$614K ﹤0.01% 4179
2019
Q4 		$31K Buy
124
+25
+25% +$2.49K ﹤0.01% 5988
2019
Q3 		$5K Buy
99
+58
+141% +$3.54K ﹤0.01% 6367
2019
Q2 		$2K Sell
41
-33
-45% -$1.7K ﹤0.01% 6461
2019
Q1 		$4K Buy
74
+36
+95% +$1.82K ﹤0.01% 6358
2018
Q4 		$1K Sell
38
-302
-89% -$14.7K ﹤0.01% 6509
2018
Q3 		$20K Buy
340
+42
+14% +$2.48K ﹤0.01% 6136
2018
Q2 		$16K Sell
298
-4,157
-93% -$1.08M ﹤0.01% 6200
2018
Q1 		$1.25M Buy
4,455
+3,895
+696% +$1.08M ﹤0.01% 4387
2017
Q4 		$131K Sell
560
-227
-29% -$53.2K ﹤0.01% 5559
2017
Q3 		$224K Buy
787
+71
+10% +$20.4K ﹤0.01% 5301
2017
Q2 		$202K Sell
716
-303
-30% -$86.7K ﹤0.01% 5324
2017
Q1 		$340K Sell
1,019
-2,410
-70% -$847K ﹤0.01% 5057
2016
Q4 		$1.13M Buy
3,429
+2,793
+439% +$751K ﹤0.01% 4374
2016
Q3 		$169K Buy
636
+187
+42% +$37.7K ﹤0.01% 5085
2016
Q2 		$60K Sell
449
-2,526
-85% -$402K ﹤0.01% 5463
2016
Q1 		$525K Sell
2,975
-534
-15% -$104K ﹤0.01% 4405
2015
Q4 		$876K Buy
3,509
+3,150
+877% +$829K ﹤0.01% 4158
2015
Q3 		$101K Buy
359
+358
+35,800% +$82.5K ﹤0.01% 5423
2015
Q2 		$0 Sell
1
-33
-97% -$5.02K ﹤0.01% 6712
2015
Q1 		$6K Buy
34
+33
+3,300% +$6.71K ﹤0.01% 6310
2014
Q4 		$0 Buy
+1
New +$142 ﹤0.01% 6631

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley's NGNE Position: Q1 2026 in Review

Morgan Stanley reduced its Neurogene (NGNE) stake by 23% in Q1 2026, selling an estimated $1.66M and leaving 285,239 shares worth $5.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4037.

Morgan Stanley first reported a position in NGNE in Q4 2014 and has held it in 46 quarters since. The position peaked at $26.3M in Q1 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Morgan Stanley held 285,239 shares of Neurogene worth $5.75M as of Q1 2026.
  • Morgan Stanley sold 85,935 Neurogene shares in Q1 2026, an estimated $1.66M.
  • Neurogene made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4037 holding.
  • Morgan Stanley first reported a position in Neurogene in Q4 2014 and has held it in 46 quarters since.
  • Morgan Stanley's Neurogene position peaked at $26.3M in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.